Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the next phase of development for its withZeta.ai platform, including planned launches of ZetaSwarm, an autonomous multi-agent AI research system, and ZetaOmics, a computational biology and multi-omic analytics toolkit. The company also unveiled new enterprise-grade capabilities designed to support institutional oncology research and drug discovery workflows.
The announcement marks a significant expansion of Lantern’s AI capabilities, which are already commercialized through the withZeta.ai platform. The platform, described as a multi-agentic AI co-scientist, is now available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. The new tools aim to enhance the platform’s ability to analyze complex biological data and accelerate the discovery of cancer therapies.
ZetaSwarm is an autonomous multi-agent AI research system that can work collaboratively on complex research tasks, potentially reducing the time and cost associated with drug discovery. ZetaOmics provides a suite of computational biology tools for multi-omic analytics, enabling researchers to integrate and analyze data from genomics, proteomics, and other omics fields. These additions are expected to strengthen the platform’s appeal to institutional researchers and pharmaceutical companies.
Lantern Pharma’s core technology is the RADR platform, which uses artificial intelligence and machine learning to identify patient populations that are most likely to benefit from specific cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The expansion of the withZeta.ai platform could have significant implications for the broader oncology research community. By making advanced AI tools available as a subscription service, Lantern is enabling other researchers and institutions to leverage computational biology and multi-agent AI without needing to develop similar capabilities in-house. This democratization of AI-driven drug discovery tools may accelerate the development of new cancer treatments and improve the efficiency of clinical trials.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s focus on precision oncology and AI-driven drug development positions it at the intersection of two rapidly evolving fields. The success of the withZeta.ai platform and its new tools will depend on adoption by the research community and the ability to demonstrate tangible improvements in drug discovery outcomes.
For more information about Lantern Pharma and its latest developments, visit the company’s newsroom at https://ibn.fm/LTRN. The full press release is available at https://ibn.fm/YpA7NA.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lantern Pharma Unveils Next Phase of withZeta.ai Platform with Multi-Agent AI and Computational Biology Tools.